Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30884766 | 0.85 | MAPT (0.51) | MAPTTDP1HTTALDH1A1LMNA | |
| SCHEMBL532654 | 0.85 | MAPT (0.51) | MAPTTDP1HTTALDH1A1LMNA | |
| SCHEMBL1961466 | 0.85 | MAPT (0.55) | MAPTTDP1HTTALDH1A1LMNA | |
| SCHEMBL28143247 | 0.84 | MAPT (0.50) | MAPTTDP1HTTLMNAMAPK1 | |
| SCHEMBL606872 | 0.83 | TDP1 (0.49) | MAPTTDP1HTTALDH1A1LMNA | |
| SCHEMBL102827 | 0.82 | MAPT (0.72) | MAPTTDP1HTTALDH1A1TUBB1 | |
| Benzene SCHEMBL27688092 | 0.81 | MAPT (0.70) | MAPTTDP1HTTALDH1A1RAB9A | |
| Hydrochloric Acid SCHEMBL5061862 | 0.81 | MAPT (0.70) | MAPTTDP1HTTALDH1A1TUBB1 | |
| Water SCHEMBL9749470 | 0.81 | MAPT (0.70) | MAPTTDP1HTTALDH1A1TUBB1 | |
| SCHEMBL27341170 | 0.81 | MAPT (0.70) | MAPTTDP1HTTALDH1A1TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114746418-B | Monocyclic beta-lactam compounds and uses thereof | 苏州信诺维医药科技股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20230110378-A1 | MONOBACTAM COMPOUND AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2023-04-13 | — | — | US | disclosed |
| EP-4074709-A1 | MONOCYCLIC BETA-LACTAM COMPOUND AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| EP-4074709-A1 | MONOCYCLIC BETA-LACTAM COMPOUND AND USE THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| CN-114746418-A | Monocyclic beta-lactam compounds and uses thereof | 苏州信诺维医药科技股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021115444-A1 | MONOCYCLIC β-LACTAM COMPOUND AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115444-A1 | MONOCYCLIC β-LACTAM COMPOUND AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-20110104055-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2011-05-05 | — | — | US | disclosed |
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060838-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | IAPP, SNCA, BACE2 | MAPT 40/4885TDP1 1853/4885HTT 45/4885 |
| US-20110104055-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | IAPP, SNCA, BACE2 | MAPT 30/4885TDP1 1700/4885HTT 40/4885 |
| US-20230110378-A1 | MONOBACTAM COMPOUND AND USE THEREOF | MGAM, MGAM2, MLEC | MAPT 1126/4885TDP1 4818/4885HTT 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.